Economic evaluation of infant and adolescent hepatitis B vaccination in the UK.

Abstract

A Markov model of hepatitis B virus (HBV) disease progression in the UK estimated that 81% of predicted HBV-associated morbidity and mortality could be prevented by universal infant vaccination at a cost of approximately £ 260,000 per QALY gained. Universal adolescent vaccination would be less effective (45% prevented) and less cost-effective (£ 493,000 per… (More)
DOI: 10.1016/j.vaccine.2010.10.075

8 Figures and Tables

Topics

  • Presentations referencing similar topics